OR WAIT null SECS
© 2021 MJH Life Sciences and Applied Clinical Trials Online. All rights reserved.
© 2021 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Click here to read the articles and download the PDF
April 13, 2021
The analysis of 330,000 clinical trials says the way the industry designs and implements trials remains to be quite primitive.
April 12, 2021
April 09, 2021
A picture of wide manufacturing violations appears in a recently disclosed FDA form 483 report on a site visit to Emergent’s Baltimore vaccine plant.
April 08, 2021
Updated programs supporting the development and review of prescription medicines are being readied for approval by federal agencies and ultimately by Congress
April 07, 2021
A look at the issues in Europe affecting ongoing trials including data management, measures being taken by sponsors, and more.
April 05, 2021
Assessing the opportunities, considerations and implications of decentralized trials—and why they’re here to stay
April 02, 2021
New American Jobs Plan set to be funded by corporate taxes will affect biopharma industry.
March 31, 2021
March 30, 2021
Lan Fong, Founder and Principal Consultant at Avery Biopharma Consulting and Venture Partner at Congress Avenue Ventures, discusses her perspective on how the pandemic is shifting the clinical trials industry.
March 29, 2021
Rate of adoption in Europe for advanced diagnostics is falling behind that of others' globally.
March 26, 2021
Valerie Powell, Vice President of Research Services at HealthiVibe, discusses her experience with obtaining patient insights and helping her clients apply them to trial design and conduct in a pandemic.
The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
March 25, 2021
The pandemic spurred an urgency to innovate that improved clinical development in ways that should benefit the industry beyond COVID-19.
FDA is reviewing the record of its accelerated approval program following recent withdrawals of certain key indications for several leading cancer therapies, based on the failure of post-approval studies to document extended benefits of treatment.